NEWS AND EVENTS
November 2022
AJK Biopharmaceutical published " Broad-spectrum antibacterial activity alone and in combination with antibiotics." J. Med. Chem. 2022, (SEE DETAILS)
September 2022
AJK Biopharmaceutical Team Participate in World AMR (Antimicrobial Resistance) Congress
August 2022
NIH Awarded a Gant to AJK Biopharmaceutical for “ Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria.
April 2022
AJK Biopharmaceutical filed a patent " Synthetic Antimicrobial peptides, US Patent App. 17/639,082, 2022. (SEE DETAILS)
March 2022
AJK Biopharmaceutical published "Amphiphilic cyclic peptide [W 4 KR 5]-antibiotics combinations as broad-spectrum antimicrobial agents. Eur. J. Med. Chem., 2022, 17, 235:114278. DOI:10.1016/j.ejmech.2022.114278. PMID: 35347995.
November 2021
AJK Biopharmaceutical filed a patent " Compositions and methods for nucleic acid delivery.PCT Int. Appl. (2021), WO 2021134026 A2 20210701.
October 2021
AJK Biopharmaceutical published " Small Amphiphilic Peptides: Activity Against Broad Range of Drug-Resistant Bacteria and Structural Insight into Membranolytic Properties. J. Med. Chem. 2022, 65, 665-687. doi:10.1021/acs.jmedchem.1c01782. PMID: 34978443.
August 2021
AJK Biopharmaceutical filed a patent "Amphiphilic peptides for nucleic acid and protein delivery. August 4, 2021, US 63/229,149 "
April 2021
AJK Biopharmaceutical filed a patent " Synthetic antimicrobial peptides PCT Int. Appl. (2021), WO 2021042039 A1 20210304.(SEE DETAILS)
Feb 2021
AJK Biopharmaceutical published " Synthesis and antiviral activity of fatty acyl conjugates of Remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. European Journal of Medicinal Chemistry, 2021, 226, 113862, (SEE DETAILS).
May 2020
AJK Biopharmaceutical published " Comparative antiviral activity of Remdesivir and anti-HIV nucleoside analogs against human coronavirus 229E (HCoV-229E). Molecules (2020) 25(10), 2343; ( SEE DETAILS )
